Shots:

• Italian pharmaceutical company- Leadiant Biosciences have gradually increased price of CDCA (chenodeoxycholic acid) from €300 year to more than €150-000- with EU’s approval in 2017 for the treatment of CTX (cerebrotendinous xanthomatosis)
• Doctors treating CTX patients at Amsterdam Medical Center are now developing a low-priced drug against Leadiant’s CDCA.
• Dutch health insurers have extended the support to Amsterdam Medical Center’s Doctors- which are temporarily funding Leadiant’s CDCA in the absence of low-priced substitute

| Ref: Financial Times | Image:  Nomen Italia